Review Article
Histone Deacetylase Inhibitors: The Epigenetic Therapeutics That Repress Hypoxia-Inducible Factors
Table 2
Major HDAC inhibitors: Targets and current status in cancer chemotherapy.
| Class | Compounds | HDACs | Status | Reference |
| Aliphatic acid | Valproic acid | Class I, IIa | Phase II clinical trials | [62] | Benzamide | MGCD0103 | Class I, II | Phase II clinical trials | [63] | Cyclic peptide | FK228 | Class I, II | FDA approved for CTCL | [64] | Hydroxamates | SAHA | Class I, II | FDA approved for CTCL | [63] | LBH589 | Class I, II | Phase II and III clinical trials | [23] | Trichostatin A | Class I, II | Experimental use | [65, 66] | Others | AR-42 | Class I, II | Started clinical trials | [67] | CUDC101 | Class I, II | Started clinical trials | [68] |
|
|
Note: Valproic acid has been in use as an anticonvulsant and mood stabilizing drug in the treatment of epilepsy and bipolar disorder.
|